Table 2.
Outcomes.
| Outcomes | Comparisons (stratified according to LVEF at baseline) | Follow-up | HR [95% CI] | p-value | I² | Studies | Samples |
| All-cause mortality | abnormal vs normal | 30-day | 2.96 [2.2, 3.98] | 0.000 | 96.3% | 13 | 813,975 |
| All-cause mortality | abnormal vs normal | 1-year | 3.14 [1.64, 6.01] | 0.000 | 99.7% | 8 | 324,723 |
| All-cause mortality | abnormal vs normal | long-term | 3.08 [2.6, 3.64] | 0.000 | 88.5% | 7 | 237,097 |
| All-cause mortality | moderate vs normal | 30-day | 2.32 [1.85, 2.91] | 0.000 | 80.8% | 9 | 807,277 |
| All-cause mortality | moderate vs normal | 1-year | 2.04 [1.37, 3.03] | 0.000 | 98.1% | 7 | 320,026 |
| All-cause mortality | moderate vs normal | long-term | 1.93 [1.54, 2.44] | 0.000 | 89.1% | 5 | 235,665 |
| All-cause mortality | poor vs normal | 30-day | 4.84 [3.83, 6.1] | 0.000 | 77.8% | 7 | 797,443 |
| All-cause mortality | poor vs normal | 1-year | 4.48 [1.37, 14.68] | 0.000 | 99.8% | 5 | 317,248 |
| All-cause mortality | poor vs normal | long-term | 6.59 [4.23, 10.27] | 0.000 | 96.7% | 5 | 235,665 |
| MACE | abnormal vs normal | 30-day | 1.9 [1.65, 2.2] | 0.000 | 76.3% | 7 | 521,584 |
| MACE | abnormal vs normal | 1-year | 1.71 [1.13, 2.59] | 0.011 | 61.2% | 3 | 6477 |
| MACE | abnormal vs normal | long-term | 1.37 [1.14, 1.65] | 0.001 | 0.0% | 4 | 14,334 |
| MACE | moderate vs normal | 30-day | 1.35 [1.27, 1.43] | 0.000 | 2.3% | 4 | 515,998 |
| MACE | moderate vs normal | 1-year | 1.19 [0.96, 1.48] | 0.107 | 0.0% | 2 | 6176 |
| MACE | moderate vs normal | long-term | 1.15 [0.87, 1.52] | 0.329 | 0.0% | 3 | 3844 |
| MACE | poor vs normal | 30-day | 2.41 [2.04, 2.85] | 0.000 | 61.3% | 4 | 515,998 |
| MACE | poor vs normal | 1-year | 1.46 [1.03, 2.08] | 0.036 | 0.0% | 2 | 6176 |
| MACE | poor vs normal | long-term | 2.31 [1.46, 3.66] | 0.000 | 0.0% | 2 | 1814 |
| Cardiac death | 40 vs 40 | 30-day | 7.54 [2.7, 21.06] | 0.000 | 56.1% | 2 | 6765 |
| Cardiac death | 40 vs 40 | 1-year | 4.51 [1.96, 10.38] | 0.000 | 0.0% | 2 | 8457 |
| Cardiac death | 40 vs 40 | long-term | 6.51 [4.25, 9.97] | 0.000 | 51.2% | 3 | 10,887 |
| CTO-Death | abnormal vs normal | all | 3.3 [2.53, 4.29] | 0.000 | 0.0% | 2 | 2841 |
| CTO-MACE | abnormal vs normal | all | 1.6 [1.34, 1.9] | 0.000 | 0.0% | 3 | 2916 |
| STEMI-Death | abnormal vs normal | 30-day | 4.36 [1.52, 12.5] | 0.000 | 96.9% | 4 | 264,475 |
| STEMI-Death | abnormal vs normal | 1-year | 5.22 [3.87, 7.04] | 0.000 | 92.8% | 3 | 233,818 |
| STEMI-Death | abnormal vs normal | long-term | 3.83 [3.35, 4.37] | 0.000 | 82.7% | 3 | 233,818 |
| STEMI-MACE | abnormal vs normal | 30-day | 3.78 [2.54, 5.64] | 0.000 | 0.0% | 2 | 2679 |
| HF-Death | HFrEF vs HFpEF | 30-day | 1.36 [1.15, 1.6] | 0.000 | 0.0% | 3 | 34,097 |
CTO, chronic total occlusion; HF, heart failure; HFrEF, HF with reduced ejection fraction; HFpEF, HF with preserved ejection fraction; HR, Hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; STEMI, ST-elevation myocardial infarction.
Bold italics mean no statistical significance.